Making cell-free DNA testing accessible to all healthcare providers
Categories: News
Published: 28 September 2025

Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore

Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore Society of Oncology (SSO ASM 2025). The session will take place on Saturday, October 4, 2025, from 09:15 to 10:00 AM (GMT+8) at Grand Ballroom 1, Level 4, Grand Copthorne Waterfront, Singapore. 

  

As oncology moves toward increasingly personalized care, Molecular Residual Disease (MRD) and multi-omics integration are emerging as critical tools for improving patient outcomes. This symposium will bring together leading experts to share evidence-based strategies and practical insights for clinical adoption and regional collaboration.   

Program Highlights: 

  • Molecular Residual Disease (MRD) in Solid Tumors: Global and Asian Insights
    Speaker: Dr Lee Chern Siang, Raffles Cancer Centre
    Dr Lee will explore the clinical utility of ctDNA-based MRD assays, including their role in recurrence monitoring, adjuvant therapy strategies, and immunotherapy management. Attendees will gain clarity on tumor-informed vs. tumor-agnostic strategies and the evolving guideline landscape. 
  • Multi-Omics and MRD Synergy to Empower Precision Oncology
    Speaker: Asst Prof Dr Tan Chia-Ken Aaron, National Cancer Centre Singapore
    Dr Tan will demonstrate how integrating DNA/RNA profiling with MRD enhances biomarker discovery, detects resistance early, and informs therapy selection. Real-world case studies will illustrate endtoend workflows—from tissue and liquid samples to results of longitudinal monitoring.  
  • Panel Discussion: Multi-Omics in APAC — Adoption, Evidence, and Next Steps
    Moderated by Ida D. Lindstroem, Global Medical Affairs Director, Gene Solutions, this dialogue will address practical considerations for implementing multi-omics workflows and opportunities for regional collaboration. 

Why this matters:
With cancer incidence rising across Asia, precision oncology is no longer optional—it is essential. This session offers oncology leaders actionable insights for MRD and multi-omics integration, supported by global evidence and APAC-specific data. 

Join us at SSO ASM 2025 to be part of the conversation shaping the future of cancer care.
For more information, visit SSO ASM 2025 website or contact Gene Solutions. 

Download Program Booklet here:  https://ssoasm.com/programme-overview/  

Molecular Residual Disease (MRD) in Solid Tumors: Global and Asian Insights Speaker: Dr Lee Chern Siang, Raffles Cancer Centre Dr Lee will explore the clinical utility of ctDNA-based MRD assays, including their role in recurrence monitoring, adjuvant therapy strategies, and immunotherapy management. Attendees will gain clarity on tumor-informed vs. tumor-agnostic strategies and the evolving guideline landscape. Multi-Omics and MRD Synergy to Empower Precision Oncology Speaker: Asst Prof Dr Tan Chia-Ken Aaron, National Cancer Centre Singapore Dr Tan will demonstrate how integrating DNA/RNA profiling with MRD enhances biomarker discovery, detects resistance early, and informs therapy selection. Real-world case studies will illustrate endtoend workflows—from tissue and liquid samples to results of longitudinal monitoring. Panel Discussion: Multi-Omics in APAC — Adoption, Evidence, and Next Steps Moderated by Ida D. Lindstroem, Global Medical Affairs Director, Gene Solutions, this dialogue will address practical considerations for implementing multi-omics workflows and opportunities for regional collaboration.